A detailed history of State Street Corp transactions in Elevation Oncology, Inc. stock. As of the latest transaction made, State Street Corp holds 1,018,026 shares of ELEV stock, worth $590,455. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,018,026
Previous 897,033 13.49%
Holding current value
$590,455
Previous $2.42 Million 74.8%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.56 - $3.02 $67,756 - $365,398
120,993 Added 13.49%
1,018,026 $610,000
Q2 2024

Aug 14, 2024

BUY
$2.35 - $5.17 $1.85 Million - $4.07 Million
786,433 Added 711.06%
897,033 $2.42 Million
Q1 2024

May 15, 2024

BUY
$0.59 - $5.13 $40,415 - $351,405
68,500 Added 162.71%
110,600 $567,000
Q1 2023

May 15, 2023

BUY
$0.75 - $2.55 $17,700 - $60,179
23,600 Added 127.57%
42,100 $79,000
Q3 2021

Nov 15, 2021

BUY
$7.66 - $16.11 $141,710 - $298,035
18,500 New
18,500 $144,000

Others Institutions Holding ELEV

About Elevation Oncology, Inc.


  • Ticker ELEV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,300,900
  • Market Cap $13.5M
  • Description
  • Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced sol...
More about ELEV
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.